Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 3, 2011

View Archived Issues

Novartis reflects on accomplishments of second quarter 2011

Byetta is safe and effective in Prader-Willi syndrome

Pfizer presents new MABA as clinical candidate for COPD

Diagnostic ability of PET tracer flutemetamol investigated in AD, MCI and NPH

Sanofi discloses novel protein kinase inhibitors

Takeda presents new histamine H3 receptor antagonists

Novel agents for protozoal infections claimed by Actelion

Piramal Life Sciences claims new diacylglycerol O-acyltransferase inhibitors

Katholieke Universiteit Leuven prepares novel antibacterials

Trial measures lorcaserin exposure in human cerebrospinal fluid

Femta Pharmaceuticals files IND with FDA for FM-101

Cardium Therapeutics provides update on plan to acquire Transdel

Noninvasive diabetes screening test obtains CE mark

Critical Outcome Technologies begins synthesis of AML drug candidates

FDA accepts NDA filing for Levadex

Genzyme seeks approval for mipomersen in Europe

Protalix replies to FDA complete response letter for taliglucerase alfa

AAV-mediated gene editing using ZFN technology shows promise to treat hemophilia in vivo

Alnylam completes phase I ALN-VSP trial

OncoTherapy Science's anticancer vaccine OTS-102 obtains generic name

Amarin completes remaining studies of AMR-101 required for NDA

Bionomics provides update on clinical trials of anticancer candidate BNC-105

Encouraging interim results emerge from phase III study of Paclical

EMA provides scientific advice regarding phase III trial of CPP-1X in FAP

European Commission expands RoActemra label

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Hippocratic loath? ‘Harm’ threat from ACIP’s proposed HBV shift
BioWorld
Individual liberty and choice vs. wider public health became one predictable hinge upon which swung the often-acerbic debates at the CDC’s Advisory Committee for...
Høeg appointment as acting CDER director tied to vaccine strategy?
BioWorld
After a more than 13-year period of stability with Janet Woodcock as the head of CDER, with Patrizia Cavazzoni taking charge during the next four years of former...
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...